One of the largest and the most sustainability challenge for all pharmaceutical companies that they are facing great changes to the industry (new products and services), With a shift in market needs towards medicines that are targeted to specific diseases and a payer community that is looking for lower cost and improved outcomes is creating strategic issues over where future investments should be made , While difficult ethical considerations persist for companies weighing the options, the less immediately profitable choices are quickly becoming as much strategic as ethical.
Leading Point can help in addressing your problem whether it is a pharmaceutical, biotech, natural health, personal care products, or medical devices you recognize, and we make the most of the opportunities that arise as the industry develops and dig to address the complexity of that market. We continuously strive to keep abreast of industry trends, drivers and issues through sharing global knowledge and industry insights. then we will help provide the sort of skills that manufacturers of pharmaceutical products require to make sure that their products are of higher caliber.
India is one of the fastest-growing pharmaceutical markets in the world, and its market size has nearly doubled since 2005. The Indian pharmaceutical market is expected to reach US$ 20 billion by 2015, growing at a compound annual growth rate (CAGR) of 11.7 % during 2005–2015 and establish its presence among the world’s leading 10 markets. India is also the third-largest market in the world in terms of volume and fourteenth in terms of value.
India accounts for 8 % of global pharmaceutical production. Indian firms produce about 60,000 generic brands across 60 therapeutic categories. In addition, Indian firms manufacture approximately 500 different active pharmaceutical ingredients (APIs). Manufacturing costs in India are approximately 35 to 40 % of those in the US due to low installation and manufacturing costs.
Moreover, India is expected to be among the world’s top five innovative hubs with contributions of around 50 % to drugs discovered worldwide. India is a fast-growing custom manufacturing outsourcing (CMO) and custom research outsourcing (CRO) destination with a growth rate for CMO thrice the global market rate.
Exports of pharmaceutical products have more than doubled over three years to around US$ 5.2 billion in 2009–2010. In 2009, India had more than120 US FDA-approved plants in addition to 84 UK MHRA-approved plants. The GoI has also introduced zeroduty for technology upgrades in the pharmaceutical sector through the Export Promotion Capital Goods Scheme (EPCG) scheme.